Netarsudil (AR-13324) dihydrochlorideis a potent, selective ROCK inhibitor with Ki of 4.2 nM for ROCK2.
Netarsudil (AR-13324) displays high selectivity, 11 kinases are inhibited >90% in a panel of 422 kinases, only ROCK1 and ROCK2 (each 93% inhibition) and PKC (delta, 91%, and eta, 93% inhibition).
Netarsudil (AR-13324) exhibts improved bioavailability, demonstrates an effective and sustained IOP reduction for 24h after dosing.
Netarsudil (AR-13324) is a novel ocular hypotensive agent for the treatment of Gglaucoma.
